Shared decision-making in multiple myeloma

In this episode, we explore why health should be seen as an investment, that delivers positive returns for individuals, economies and society as a whole.Hosted by Nicole Raleigh of Pharmaphorum, the conversation brings together perspectives from J&J Innovative Medicine and economic research institute, WifOR to unpack the social and economic value of health, the consequences of short-term thinking and why long-term, sustainable investment in health is essential for future prosperity. This recording was organised and funded by Johnson & Johnson. March 2026 CP-562493  Hosted on Acast. See acast.com/privacy for more information.

This episode focuses on precision medicine in cancer – why it’s considered so revolutionary, and how we can work together to make it more accessible to every patient.Our experts offer their perspectives on the challenges within the treatment pathway and infrastructure, as well as potential solutions that could help increase access and uptake. This recording was organised and funded by Johnson & Johnson.October 2025CP-530938 Hosted on Acast. See acast.com/privacy for more information.

In this episode, our experts shine a light on the benefits of endoscopy in the long-term management of inflammatory bowel disease (IBD).   Despite the valuable role of endoscopy, there are still barriers to its adoption in care pathways. We explore why that is, and how we need to shift perceptions and work collaboratively to improve long-term patient outcomes in IBD.  This recording was organised and funded by Johnson & Johnson.September 2025CP-530931 Hosted on Acast. See acast.com/privacy for more information.

In this episode, we talk about the importance of shared decision-making in helping patients achieve a “life of possibility”, especially in complex illnesses like multiple myeloma. Our experts discuss the barriers that prevent patients and HCPs from being equal partners, how shared decision-making leads to better decision-making, and the critical role of advocacy groups in empowering patients to have a greater say in their treatment pathway.This recording was organised and funded by Johnson & Johnson August 2025CP-530923 | CP-530918 Hosted on Acast. See acast.com/privacy for more information.

In the final episode of Season 2, we look at the future of healthcare in Central Europe and the Baltics, a diverse region that covers almost one third of EU countries.  Tuba Atahan, Managing Director, and Laura Saar, Market Access Director, for Central Europe and Baltics delve into the current barriers to healthcare access in the region – such as the growing disparity in multiple myeloma care – and discuss innovative solutions that will help close the gap. This recording was organised and funded by Johnson & Johnson November 2024CP-485355 | CP-485428 Hosted on Acast. See acast.com/privacy for more information.

In this episode, we find out how the healthcare industry and academic institutions are working together to find solutions to a decreasing healthcare workforce.  Giuseppe Pompilio, Director of Market Access, Johnson & Johnson, Italy, joins us to discuss the results of a recent academic partnership and the new healthcare roles that are key to progressing patient care. This recording was organised and funded by Johnson & Johnson October 2024CP-479290 | CP-479287 Hosted on Acast. See acast.com/privacy for more information.

In this episode, we explore the current pressure on Europe’s healthcare resources and how partnerships can help reduce inefficiencies and take us forward – with examples from the Nordic region. As the need for value-based healthcare becomes more apparent, we speak to Sofia Iqbal, Real-World Evidence Strategic Partnerships Lead for EMEA, about how collaboration identifies innovative solutions that could ultimately improve patient care. This recording was organised and funded by Johnson & Johnson October 2024CP-478884 | CP-478875 Hosted on Acast. See acast.com/privacy for more information.

In this episode, we’re speaking with an expert in Switzerland to better understand the role of research and development, manufacturing, and supply chain in creating an ecosystem that fosters healthcare innovation.We also discuss some potential real-world solutions and explore how talented people, in the right environment, make Switzerland such a unique hub for science, innovation and excellence in Europe.This recording was organised and funded by Johnson & Johnson July 2024CP-463603 Hosted on Acast. See acast.com/privacy for more information.

In this episode, we’re looking at the unique approach France has taken to try and get new and innovative treatments to patients faster, and what other national health bodies could learn from this process.Joining us is an expert in market access and health policy, who has been at the forefront of recent regulatory changes in France and brings with her a wealth of knowledge from a career spanning three decades in pharmaceuticals.This recording was organised and funded by Johnson & Johnson June 2024 CP-460651 Hosted on Acast. See acast.com/privacy for more information.

In this episode, we’re joined by experts from Belgium, Luxembourg and the Netherlands, three nations that sit in the heart of the EU and take a collaborative approach to pharmaceuticals and healthcare.We explore what challenges they are facing when new and innovative medicines are on the way to being authorised, what solutions are being pursued to ensure these treatments reach patients, and what this could mean for other countries in Europe.This recording was organised and funded by Johnson & Johnson June 2024 CP-460080  Hosted on Acast. See acast.com/privacy for more information.